Antibiotic Nanoparticles-Loaded Wound Dressings Against Pseudomonas aeruginosa's Skin Infection: A Systematic Review

María I Quiñones-Vico1,2,3,4, Ana Ubago-Rodríguez1,2,3, Ana Fernández-González1,2,3

  • 1Cell Production and Tissue Engineering Unit, Virgen de las Nieves University Hospital, Granada, 18014, Spain.

Insights

Novel wound dressings combining nanoparticles (NPs) with antibiotics show promise for treating Pseudomonas aeruginosa infections. However, clinical trials are needed to confirm the safety and efficacy of these advanced antibiotic nanoparticle wound dressings.

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Infectious Diseases

Background:

  • Pseudomonas aeruginosa is a multidrug-resistant nosocomial pathogen causing severe infections.
  • Conventional antibiotic treatments for wound infections have limitations including toxicity and resistance.
  • Nanoparticle-loaded wound dressings offer a promising strategy to enhance antibiotic safety and efficacy.

Purpose of the Study:

  • To review and analyze the latest research on wound dressings loaded with antibiotic nanoparticles.
  • To evaluate the properties, antimicrobial activity, and biocompatibility of various nanoparticle-based wound dressing strategies.
  • To identify research gaps and future directions for clinical translation.

Main Methods:

  • Systematic literature search for studies on antibiotic nanoparticle-loaded wound dressings.
  • Analysis of nanoparticle properties, wound dressing characteristics, and antimicrobial efficacy.
  • Assessment of biocompatibility and safety data from evaluated studies.

Main Results:

  • Most research focuses on silver nanoparticles (57.1%) and other inorganic nanoparticles (22.4%).
  • Polymeric nanoparticles (14.3%) and carbon-based nanoparticles (6.1%) are also explored.
  • No clinical trials have yet evaluated the efficacy of these nanoparticle-loaded wound dressings in patients.

Conclusions:

  • Nanoparticle-loaded wound dressings represent an innovative approach for managing Pseudomonas aeruginosa infections.
  • Further research is essential to ensure treatment safety and facilitate clinical application.
  • Bridging the gap between laboratory findings and patient bedside is crucial for therapeutic advancement.